An FDA advisory panel on Thursday narrowly recommended that the agency reclassify four popular unproven peptides—including two used in the so-called "Wolverine stack"—to allow compounding pharmacies to legally manufacture and dispense them. The vote, eight to six with one abstention for three peptides, and seven to five with two abstentions for MOTs-C, could reshape the pharmaceutical manufacturing landscape for these substances, which currently exist in a largely unregulated gray market.
The FDA Panel Vote
According to WIRED, the panel of experts heard more than 11 hours of testimony from FDA staff, healthcare practitioners, patients, pharmacies, and clinics. The FDA's own scientists recommended against allowing compounding pharmacies to produce any of the seven peptides under consideration, citing a lack of evidence showing they are safe and effective. Despite this, the panel voted in favor of BPC-157, KPV, and TB-500 for the agency's bulks list, enabling compounders to create custom medications with them. The fourth peptide, MOTs-C, also received a favorable vote. The advisory panel is scheduled to consider three more peptides on Friday.
"I'm not going to tell you that the evidence for BPC-157 is strong. It isn't, and I won't overclaim it," said Anant Vinjamoori, chief medical officer of telehealth provider Hims & Hers, which is actively preparing to launch peptide treatments in anticipation of FDA approval. Committee members were asked to evaluate BPC-157 for ulcerative colitis, though it is widely marketed for tissue repair and recovery.
The Gray Market and Supply Chain Risks
Many peptides currently operate in an unregulated gray market after the Biden administration banned compounding pharmacies from producing 20 peptides in 2023 due to safety concerns. According to WIRED, China and India are major suppliers of peptides, with some crypto-funded fentanyl labs switching gears to produce them. This highlights significant supply chain vulnerabilities for manufacturers.
During the meeting, healthcare providers testified that patients had turned to the gray market and received products laced with illicit substances. However, John Hertig, chair of the Collaborative for Evidence-Based Medicines, argued that allowing compounders to produce these peptides sends a confusing message to patients about FDA approval. He warned that a gray market would persist, citing the continued demand for unapproved GLP-1 drugs despite FDA-approved alternatives.
| Peptide | Vote | Intended Use (as discussed) | Concerns |
|---|---|---|---|
| BPC-157 | 8-6-1 | Tissue repair, ulcerative colitis | Lack of human studies; WADA safety risk |
| KPV | 8-6-1 | Anti-inflammatory (implied) | Lack of safety/effiacy evidence |
| TB-500 | 8-6-1 | Recovery (part of "Wolverine stack") | Lack of evidence |
| MOTs-C | 7-5-2 | Mitochondrial function (implied) | Lack of evidence |
Implications for Pharmaceutical Manufacturing
The panel's recommendation, though non-binding, could open the door for compounding pharmacies to scale production of these peptides. Hims & Hers is already preparing to launch treatments, signaling potential demand for raw peptide materials. However, the sourcing of these ingredients from China and India presents quality and regulatory challenges. The FDA has not yet made a final decision, and the agency's own scientists opposed the reclassification.
Critics like Adriane Fugh-Berman, a physician and professor at Georgetown University, challenged the idea that compounding would eliminate gray market risks. The World Anti-Doping Agency has stated that BPC-157 poses a risk to athlete health due to insufficient human studies.
What's Next
Manufacturing executives should monitor the FDA's final decision on the bulks list, which could create new opportunities for compounding pharmacies but also increase scrutiny on peptide supply chains. The panel will continue deliberations on additional peptides, and the outcome may influence how pharmaceutical manufacturers approach unapproved active ingredients sourced from overseas.
For now, the peptide market remains a complex mix of regulated compounding, gray market sales, and overseas supply chains. The FDA's next steps will determine whether the manufacturing landscape for these substances becomes more structured or continues to operate in the shadows.
